Brian Lian - Viking Therapeutics CEO and President and Director
| VKTX Stock | USD 28.35 1.72 5.72% |
CEO
Dr. Brian W. Lian, Ph.D., is President, Chief Executive Officer, Director of the Company. He has served as our President and Chief Executive Officer and as a Director since our inception in September 2012. Dr. Lian has over 15 years of experience in the biotechnology and financial services industries. Prior to joining Viking, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, an investment bank, from 2012 to 2013. At SunTrust Robinson Humphrey, he was responsible for coverage of small and midcap biotechnology companies with an emphasis on companies in the diabetes, oncology, infectious disease and neurology spaces. Prior to SunTrust Robinson Humphrey, he was Managing Director and Senior Research Analyst at Global Hunter Securities, an investment bank, from 2011 to 2012. Prior to Global Hunter Securities, he was Senior Healthcare Analyst at The Agave Group, LLC, a registered investment advisor, from 2008 to 2011. Prior to The Agave Group, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, an investment bank, from 2006 to 2008. Prior to CIBC, he was a research scientist in small molecule drug discovery at Amgen, a biotechnology company. Prior to Amgen, he was a research scientist at Microcide Pharmaceuticals, a biotechnology company. Dr. Lian has served as a member of the board of directors of Seelos Therapeutics, Inc. since January 2019 since 2015.
| Age | 59 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 |
| Phone | 858 704 4660 |
| Web | https://www.vikingtherapeutics.com |
Latest Insider Transactions
Lian holds an MBA in accounting and finance from Indiana University, an MS and Ph.D. in organic chemistry from The University of Michigan, and a BA in chemistry from Whitman College.Brian Lian Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Lian against Viking Therapeutics stock is an integral part of due diligence when investing in Viking Therapeutics. Brian Lian insider activity provides valuable insight into whether Viking Therapeutics is net buyers or sellers over its current business cycle. Note, Viking Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Viking Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Lian over three months ago Disposition of 35000 shares by Brian Lian of Viking Therapeutics at 23.95 subject to Rule 16b-3 | ||
Brian Lian over six months ago Disposition of 1000 shares by Brian Lian of Viking Therapeutics at 69.9 subject to Rule 16b-3 | ||
Brian Lian over six months ago Disposition of 140000 shares by Brian Lian of Viking Therapeutics at 4.65 subject to Rule 16b-3 |
Viking Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1477) % which means that it has lost $0.1477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.179) %, meaning that it created substantial loss on money invested by shareholders. Viking Therapeutics' management efficiency ratios could be used to measure how well Viking Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.13 in 2025. Return On Capital Employed is likely to drop to -0.18 in 2025. At this time, Viking Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 952.6 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 794.1 K in 2025.Similar Executives
| Found 12 records | CEO Age | ||
| Andrew MD | Akero Therapeutics | 58 | |
| Douglas Esq | Sarepta Therapeutics | 62 | |
| Eric MBA | Seres Therapeutics | 49 | |
| Paula Ragan | X4 Pharmaceuticals | 55 | |
| John Baird | PTC Therapeutics | N/A | |
| Jeremy MBA | Day One Biopharmaceuticals | 54 | |
| Denise ScotsKnight | Mereo BioPharma Group | 66 | |
| FACS MD | PTC Therapeutics | 52 | |
| William Sibold | Madrigal Pharmaceuticals | 59 | |
| Daniel MBA | Acumen Pharmaceuticals | 55 | |
| Stuart Peltz | PTC Therapeutics | 65 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.15 |
Viking Therapeutics Leadership Team
Elected by the shareholders, the Viking Therapeutics' board of directors comprises two types of representatives: Viking Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viking. The board's role is to monitor Viking Therapeutics' management team and ensure that shareholders' interests are well served. Viking Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viking Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Michael Morneau, Vice Administration | ||
| Marianne Mancini, Chief Officer | ||
| Geoffrey Barker, Senior Development | ||
| Brian Lian, CEO and President and Director | ||
| Gregory Zante, Vice President - Finance and Operations |
Viking Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viking Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 2.47 B | ||||
| Shares Outstanding | 112.25 M | ||||
| Shares Owned By Insiders | 2.00 % | ||||
| Shares Owned By Institutions | 74.20 % | ||||
| Number Of Shares Shorted | 25.11 M | ||||
| Price To Earning | (3.17) X | ||||
| Price To Book | 3.83 X | ||||
| EBITDA | (150.92 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.